810220 | C6-NBD Galactosyl Ceramide
N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-galactosyl-ß1-1'-sphingosine
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
C6-NBD Galactosyl Ceramide
N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-galactosyl-ß1-1'-sphingosine
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by BiozBen-David O, Pewzner-Jung Y, Brenner O, Laviad EL, Kogot-Levin A, Weissberg I, Biton IE, Pienik R, Wang E, Kelly S, Alroy J, Raas-Rothschild A, Friedman A, Brügger B, Merrill AH Jr, Futerman AH. Encephalopathy caused by ablation of very long acyl chain ceramide synthesis may be largely due to reduced galactosylceramide levels. J Biol Chem. 2011 Aug 26;286(34):30022-33. doi: 10.1074/jbc.M111.261206. Epub 2011 Jun 24. PMID: 21705317; PMCID: PMC3191043.
PubMed ID: 21705317- Certificate of Analysis (Lot No. 810220C-250UG-A-012 and 5391CEA012)
- Certificate of Analysis (Lot No. 810220P-250UG-A-012 and 5391PEA012)
- Certificate of Analysis (Lot No. 810220C-250UG-B-012 and 5391CEB012)
- Certificate of Analysis (Lot No. 810220P-250UG-B-012 and 5391PEB012)
